S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
PRI   135.68 (+1.03%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
DIS   147.66 (+0.15%)
S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
PRI   135.68 (+1.03%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
DIS   147.66 (+0.15%)
S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
PRI   135.68 (+1.03%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
DIS   147.66 (+0.15%)
S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
PRI   135.68 (+1.03%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
DIS   147.66 (+0.15%)
Log in

NYSE:ARPO - Aerpio Pharmaceuticals Stock Price, Forecast & News

$0.56
-0.03 (-5.08 %)
(As of 12/6/2019 04:00 PM ET)
Today's Range
$0.55
Now: $0.56
$0.60
50-Day Range
$0.46
MA: $0.54
$0.62
52-Week Range
$0.45
Now: $0.56
$4.25
Volume169,400 shs
Average Volume250,169 shs
Market Capitalization$22.73 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio. Aerpio Pharmaceuticals, Inc.(OTCPK:ARPO) operates independently of Akebia Therapeutics, Inc. as of December 22, 2011.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone513-985-1920

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$22.73 million
Next Earnings Date3/3/2020 (Estimated)
OptionableNot Optionable

Receive ARPO News and Ratings via Email

Sign-up to receive the latest news and ratings for ARPO and its competitors with MarketBeat's FREE daily newsletter.


Aerpio Pharmaceuticals (NYSE:ARPO) Frequently Asked Questions

What is Aerpio Pharmaceuticals' stock symbol?

Aerpio Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "ARPO."

When is Aerpio Pharmaceuticals' next earnings date?

Aerpio Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Aerpio Pharmaceuticals.

What is the consensus analysts' recommendation for Aerpio Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerpio Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aerpio Pharmaceuticals.

Has Aerpio Pharmaceuticals been receiving favorable news coverage?

Media coverage about ARPO stock has been trending somewhat negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aerpio Pharmaceuticals earned a news sentiment score of -1.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Aerpio Pharmaceuticals.

Who are some of Aerpio Pharmaceuticals' key competitors?

What other stocks do shareholders of Aerpio Pharmaceuticals own?

Who are Aerpio Pharmaceuticals' key executives?

Aerpio Pharmaceuticals' management team includes the folowing people:
  • Dr. Stephen J. Hoffman, CEO & Director (Age 65)
  • Dr. Joseph H. Gardner, Founder, Pres & Director (Age 63)
  • Mr. Michael W. Rogers, Chief Financial Officer (Age 59)
  • Dr. Stephen Pakola, Chief Medical Officer (Age 50)
  • Mr. Kevin G. Peters, Chief Scientific Officer (Age 62)

How do I buy shares of Aerpio Pharmaceuticals?

Shares of ARPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aerpio Pharmaceuticals' stock price today?

One share of ARPO stock can currently be purchased for approximately $0.56.

How big of a company is Aerpio Pharmaceuticals?

Aerpio Pharmaceuticals has a market capitalization of $22.73 million. View Additional Information About Aerpio Pharmaceuticals.

What is Aerpio Pharmaceuticals' official website?

The official website for Aerpio Pharmaceuticals is http://www.aerpio.com/.

How can I contact Aerpio Pharmaceuticals?

The company can be reached via phone at 513-985-1920.


MarketBeat Community Rating for Aerpio Pharmaceuticals (NYSE ARPO)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  38 (Vote Outperform)
Underperform Votes:  50 (Vote Underperform)
Total Votes:  88
MarketBeat's community ratings are surveys of what our community members think about Aerpio Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARPO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Featured Article: What is the CAC 40 Index?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel